Amneal Pharmaceuticals (AMRX) Non-Current Deferred Tax Liability (2017 - 2018)

Amneal Pharmaceuticals' Non-Current Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $1.2 million for Q4 2018.

• On a quarterly basis, Non-Current Deferred Tax Liability fell 64.16% year-over-year to $1.2 million in Q4 2018; TTM through Dec 2018 was $1.2 million, a 64.16% decrease from a year earlier, with the FY2018 full-year figure at $1.2 million, down 64.16% from the prior year.
• Non-Current Deferred Tax Liability retreated to $1.2 million in Q4 2018 per AMRX's latest filing, from $1.8 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $3.3 million in Q4 2017 and bottomed at $1.2 million in Q4 2018.